SH3RF1

Across TCGA pan-cancer cohorts, SH3RF1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SH3RF1 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SH3RF1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SH3RF1 expression acts as an unfavorable survival marker.

LUAD, BRCA, and STAD are the cancer types where SH3RF1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.053	0.751	<.001	36	view →
BRCA	OS	Median	III,IV	0.001	0.907	<.001	12	view →
STAD	DFS	Median	III,IV	0.156	0.489	.040	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	0.283	0.784	.001	6	view →
LIHC	OS	Median	II,III,IV	0.152	0.614	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SH3RF1–LUAD (OS)

Open the LUAD breakdown →